X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Roche Pharmaceutical Manufacturing Plant

Yuvraj_pawp by Yuvraj_pawp
8th August 2014
in Europe, Projects

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Roche Mustahzarlari has completed the construction of their pharmaceutical facility at Gebze, close to Istanbul, Turkey. The new drugs manufacturing facility will make solid dosage forms, including packaging of the finished products. The facility, which has a floor space of 18,000m², includes new quality control laboratories, warehousing, offices and administration buildings.

The facility is Roche’s second-largest solid forms production plant. The project was valued at approximately $60 million. Work on the new plant began in July 2000 and, now completed, it is scheduled to begin production on 20 October 2003. The plant will produce 61 million packages of medicine in the first year. This will meet fully the domestic market demand for capsules and tablets and also allow some export to Eastern Europe.

PHARMACEUTICAL PLANT CONSTRUCTION

The Roche subsidiary decided to award the lead contract for the pharmaceutical manufacturing plant to Foster Wheeler Italiana SpA. The contract was for the provision of engineering, procurement and construction management. Foster Wheeler managed the main part of the work from its Italian centre in Milan.

TRANSITION PHASE

The plant is scheduled to enter production in October 2003. However, for the first few months this will only involve packaging. The older and smaller Roche plant at Levent, Turkey will continue production during a transition phase to the new plant.

Rockwell Automation are implementing a logistics software and production package – Propack Data PMX MESTM – to assist Roche in the transport of products between the plants, dispensing and packaging the products and their subsequent distribution from a fully automated warehousing facility to customers in Eastern Europe.

HARD GELATINE CAPSULES AND SOFT ELASTIC CAPSULES

The plant will make capsules of solid dosage forms, in which one or more medicinal and inert ingredients are enclosed in a small shell or container usually made of gelatine. The plant will make both hard gelatine capsules and soft elastic capsules.

Hard gelatine capsules are made out of a larger portion (the body) and a smaller section (the cap). Both commercially and extemporaneously, the method of filling requires that the amount of powder containing the given dose must be matched with the volume contained in the body of the capsule. Conventional capsules are oblong with curved ends. They are usually clear but can be coloured during manufacture by incorporating a water-soluble dye in the gelatine solution. The solution is then coated on moulds and dried. Hard gelatine capsules are used to hold dry powders. They dissolve in water and immediately release the contents. They are capable of holding oil drugs but they must be sealed to do so.

Soft capsules are useful for liquids and for materials with a distinct odour. They are made of gelatine, but additional materials are added to make them elastic. They cannot be made extemporaneously, and must be sealed after filling.

Tags: Europe
Previous Post

Quintiles Drug Research Unit

Next Post

Vivalis R&D Facility

Related Posts

U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
API manufacturing quality and regulatory trends
Insights

API Manufacturing Quality and Regulatory Trends

26th September 2025
Scottish Pharma Sector
Europe

ABPI Launches Manifesto to Advance Scottish Pharma Sector

23rd September 2025
DCS Lab Project
Asia

MGI Tech and JCBio Advance Multi-Omics with DCS Lab Project

4th September 2025
Pharmaceutical Tariff
Americas

Pharmaceutical Tariff Agreed at 15% Under US-EU Trade Deal

26th August 2025
Biosimilar Ranibizumab
Asia

Lupin, Sandoz Collab to Commercialise Biosimilar Ranibizumab

18th August 2025
Next Post

Vivalis R&D Facility

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In